| Members |
targetComponentId |
| Depression NOS |
Depressive disorder |
| Depression, ikke nærmere specificeret |
Depressive disorder |
| Depressor anguli oris flap |
Depressor anguli oris myocutaneous flap |
| Depth of CVS examination NOS |
Cardiovascular examination finding |
| Depth of CVS examination NOS |
Depth of CVS examination |
| Depth of GIT examination NOS |
Gastrointestinal test observable |
| Depth of GU examination NOS |
Genitourinary examination finding |
| Depth of GU examination NOS |
Depth of genitourinary examination |
| Depth of cells in anterior chamber |
Depth of anterior chamber |
| Depth of examination NOS |
Depth of examination |
| Depth of examination NOS |
Depth of examination |
| Depth of gastrointestinal tract examination NOS |
Depth of gastrointestinal tract examination (situation) |
| Depth of general examination NOS |
Depth of general examination |
| Depth of general examn. NOS |
Depth of general examination |
| Depth of resp. examn. NOS |
Respiratory examination finding |
| Depth of respiratory examination NOS |
Depth of respiratory system examination |
| Derangement of meniscus, NEC |
Derangement of meniscus |
| Dermal appendage removal NOS |
Removal of dermal appendage |
| Dermal appendage removal NOS |
Removal of dermal appendage |
| Dermatitis atrophicans |
Acrodermatitis atrophicans chronica |
| Dermatit forårsaget af indtaget lægemiddel OG/ELLER medicin |
Dermatitis caused by substance taken via oral route (disorder) |
| dermatit forårsaget af indtagne stoffer |
Dermatitis caused by substance taken via oral route (disorder) |
| Dermatitis due to other specified substance taken internally |
Dermatitis caused by substance taken via oral route (disorder) |
| dermatofibrom |
Dermatofibroma (morphologic abnormality) |
| Dermatoses NOS |
Disorder of skin (disorder) |
| Dermatoses NOS |
Disorder of skin (disorder) |
| dermatose som kan tilskrives antikoagulans indeholdende cumarin |
Dermatosis caused by coumarin (disorder) |
| dermatose med mistanke om viral ætiologi |
Suspected viral infection of skin (situation) |
| Dermatose forårsaget af immunsuppressiv behandling |
Dermatosis caused by immunosuppressant |
| Dermographism |
Dermatographic urticaria |
| Deroofing of cyst of organ NOC |
Intentional, structural alteration of the human body by mechanical, thermal, light-based, electromagnetic, or chemical means, and/or by the incision or destruction of tissues using instruments to cut, burn, vaporize, freeze, suture, probe, or manipulate by closed reductions. |
| væskeformigt desfluran 99 % |
Product containing precisely desflurane 990 milligram/1 milliliter conventional release solution for inhalation (clinical drug) |
| desloratadin 0,5 mg/ml syrup |
Product containing precisely desloratadine 500 microgram/1 milliliter conventional release oral solution (clinical drug) |
| desloratadin 2,5 mg + pseudoephedrin 120 mg tablet med modificeret udløsning |
Product containing only desloratadine and pseudoephedrine in oral dose form (medicinal product form) |
| Desloratadine 2.5mg/pseudoephedrine 120mg prolonged-release oral tablet |
Product containing only desloratadine and pseudoephedrine in oral dose form (medicinal product form) |
| desloratadin 5 mg + pseudoephedrin 240 mg tablet med modificeret udløsning |
Product containing only desloratadine and pseudoephedrine in oral dose form (medicinal product form) |
| Desloratadine 5mg/pseudoephedrine 240mg prolonged-release oral tablet |
Product containing only desloratadine and pseudoephedrine in oral dose form (medicinal product form) |
| Desmoplastisk fibrom |
Desmoplastic fibroma (morphologic abnormality) |
| desmoplastisk juvenilt gangliogliom |
Desmoplastic infantile astrocytoma |
| desmopressinacetat 0,01 % opløsning |
Product containing only desmopressin (medicinal product) |
| desoximetason 0,5 % gel |
Product containing only desoximetasone (medicinal product) |
| Destruction of intervertebral disc by other specified method |
Vertebral column destructive procedure |
| Destruction of lesion NOS |
Destruction of lesion |
| Destruction of lesion NOS |
Destruction of lesion |
| destruktion af morfologisk forandring i kvindeligt perineum |
Destruction of lesion of perineum |
| destruktion af morfologisk forandring i kvindeligt perineum, ikke klassificeret andetsteds |
Destruction of lesion of perineum |
| Destruction of lesion of organ NOC NOS |
Destruction of lesion |
| Destruction of lesion of organ NOC OS |
Destruction of lesion |
| Destruction of tissue of heart |
Catheter ablation of tissue of heart |
| Destruction of tissue of pharynx |
Pharynx destructive procedure |
| Destructive procedure of facial bone |
Facial bone destructive procedure |
| destruktivt indgreb på foster for at fremme forløsningen |
Destruction of fetus |
| Desulfotomaculum orientis |
Desulfosporosinus orientis (organism) |
| Detachment of left retina co-occurrent with retinal defect |
Detachment of left retina with retinal break |
| Detachment of right retina co-occurrent with retinal defect |
Detachment of right retina with retinal break |
| påvisning af gift |
Measurement of substance (procedure) |
| Detrusorhyperrefleksi i blæren |
Neurogenic detrusor overactivity |
| Detrusor instability |
Idiopathic detrusor overactivity (disorder) |
| Detrusor instability |
Idiopathic detrusor overactivity (disorder) |
| Detrusor instability |
Idiopathic detrusor overactivity (disorder) |
| Detrusorinstabilitet i blæren |
Idiopathic detrusor overactivity (disorder) |
| Screening for udviklingshandicap |
Screening for developmental disorder (procedure) |
| dexamethason 0,5 mg/5 ml eliksir |
Dexamethasone 100 microgram/mL oral solution |
| Dexamethasone sodium phospha 0.05% |
Dexamethasone only product in ocular dose form |
| Dexamethasone sodium phosphate 0.05% conventional release eye drops |
Dexamethasone only product in ocular dose form |
| dexamethasonnatriumphosphat 0,5 %, øjendråber til engangsbrug |
Dexamethasone only product in ocular dose form |
| dexamethason 0,1 % + hypromellose 0,5 % øjendråber |
Dexamethasone 1 mg/mL and hypromellose 5 mg/mL eye solution |
| ikke-farmaceutisk dexamphetamin |
Dexamfetamine |
| Dexlansoprazole 30mg dual delayed-release oral capsule |
Dexlansoprazole 30 mg gastro-resistant oral capsule |
| Dexlansoprazole 30mg m/r capsule |
Dexlansoprazole 30 mg gastro-resistant oral capsule |
| Dexlansoprazole 60mg dual delayed-release oral capsule |
Product containing precisely dexlansoprazole 60 milligram/1 each gastro-resistant oral capsule (clinical drug) |
| Dexlansoprazole 60mg m/r capsule |
Product containing precisely dexlansoprazole 60 milligram/1 each gastro-resistant oral capsule (clinical drug) |
| dexmethylphenidat 20 mg kapsel med modificeret udløsning |
Product containing precisely dexmethylphenidate hydrochloride 20 milligram/1 each prolonged-release oral capsule (clinical drug) |
| Dexmethylphenidate 20mg prolonged-release oral capsule |
Product containing precisely dexmethylphenidate hydrochloride 20 milligram/1 each prolonged-release oral capsule (clinical drug) |
| dexmethylphenidat 5 mg kapsel med modificeret udløsning |
Dexmethylphenidate hydrochloride 5 mg prolonged-release oral capsule |
| Dexmethylphenidate 5mg prolonged-release oral capsule |
Dexmethylphenidate hydrochloride 5 mg prolonged-release oral capsule |
| dexonl-patch |
Prosthetic patch |
| Dexon-sutur |
Polyglycolic acid suture |
| dexrazoxanhydrochlorid |
Product containing dexrazoxane (medicinal product) |
| Dekstran 40 (10 %) injektionsvæske, opløsning, flaske a 500 ml |
Dextran 40 100 mg/mL solution for injection |
| Dextran 40 10% injection |
Dextran 40 100 mg/mL solution for injection |
| dexstran 40/glucose 5 % infusionsvæske, opløsning, pose |
Dextran 40 100 mg/mL solution for injection |
| Dextran 40 + natriumchlorid 0,9 % infusionsvæske, opløsning, pose |
Dextran 40 100 mg/mL solution for injection |
| Dextran 70 in sodium chloride 7.5% infusion |
Dextran 70 only product in parenteral dose form |
| dextran 70 i natriumchlorid 7,5 % infusionsvæske, opløsning |
Dextran 70 only product in parenteral dose form |
| dextran 70 + glucose 5 % infusionsvæske, opløsning, pose |
Dextran 70 only product in parenteral dose form |
| Dextran 70/natriumchlorid 0,9 % infusionsvæske, opløsning, pose |
Dextran 70 only product in parenteral dose form |
| allergi over for dextran |
Non-allergic hypersensitivity to dextran (finding) |
| dextroamphetaminsulfat 10 mg kapsel med modificeret udløsning |
Dexamfetamine only product in oral dose form |
| Dextroamphetamine sulfate 10mg prolonged-release oral capsule |
Dexamfetamine only product in oral dose form |
| dextroamphetaminsulfat 15 mg kapsel med modificeret udløsning |
Dexamfetamine only product in oral dose form |
| Dextroamphetamine sulfate 15mg prolonged-release oral capsule |
Dexamfetamine only product in oral dose form |
| dextroamphetaminsulfat 5 mg kapsel med modificeret udløsning |
Dexamfetamine only product in oral dose form |
| Dextroamphetamine sulfate 5mg prolonged-release oral capsule |
Dexamfetamine only product in oral dose form |
| dextromethorphan 7,5 mg pastil |
Dextromethorphan 7.5 mg oromucosal lozenge |
| dextromethorphanhydrobromid 15 mg + promethazinhydrochlorid 6,25 mg væske |
Dextromethorphan hydrobromide 3 mg/mL and promethazine hydrochloride 1.25 mg/mL oral solution |
| dextromethorphanhydrobromid 6,67 mg/5 ml syrup |
Dextromethorphan hydrobromide 1.33 mg/mL oral solution |
| dextromethorphanhydrobromid 7,5 mg/5 ml eliksir til oral anvendelse |
Product containing precisely dextromethorphan hydrobromide 1.5 milligram/1 milliliter conventional release oral solution (clinical drug) |
| dextromethorphanhydrobromid 7,5 mg/5 ml syrup |
Product containing precisely dextromethorphan hydrobromide 1.5 milligram/1 milliliter conventional release oral solution (clinical drug) |
| allergi over for dextromethorphanhydrobromid |
Allergy to dextromethorphan |
| Dextrose + lidocaine hydrochloride 7.5%ww/1.5%ww injection |
Lidocaine only product in parenteral dose form |
FHIR